Zentalis Issues $75M Equity Offering Seven Days After Cash Guidance
Runway Extension
Company Background
Zentalis Pharmaceuticals is a San Diego-based clinical oncology company with no approved products and no revenue, built around a single investigational asset: azenosertib, a WEE1 kinase inhibitor being developed for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The company restructured in early 2025, cutting costs and focusing entirely on this biomarker-selected indication, which management estimates covers roughly 50% of the platinum-resistant ovarian cancer population.
Two registration-oriented trials are currently running. DENALI is a Phase 2 trial designed to support a potential FDA accelerated approval; Part 2 is enrolling across three cohorts and was initially expected to produce a topline readout by year-end 2026. ASPENOVA is a 420-patient Phase 3 randomized trial comparing azenosertib to chemotherapy, designed to support full approval; the first patient was dosed in May 2026. Both trials are enrolling simultaneously, which has driven a step-up in spending.
The company's cash position has declined steadily as trials have ramped: from $371 million at the end of 2024 to $245.9 million at year-end 2025, $211.8 million at March 31, 2026, and $174.6 million at June 30, 2026. Net losses have accelerated in tandem, with the second quarter of 2026 producing a $42.3 million loss, up from $35.4 million in the first quarter.
What Was Disclosed
On August 13, 2026, Zentalis entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. to sell 23 million shares of common stock at $3.50 per share. After underwriting discounts and estimated offering expenses, net proceeds are approximately $75.1 million. The offering closed August 17, 2026, subject to customary conditions. Underwriters also received a 30-day option to purchase up to an additional 3.45 million shares at the same price.